Preclinical studies of dual-photosensitizer PDT combined with optical clearing for treatment of cutaneous melanoma (Conference Presentation)

Layla Pires; Ana Gabriela Sálvio M.D.; Vanderlei S. Bagnato; Brian C. Wilson; Cristina Kurachi

doi:10.1117/12.2288539

14 March 2018 Preclinical studies of dual-photosensitizer PDT combined with optical clearing for treatment of cutaneous melanoma (Conference Presentation)

Layla Pires, Ana Gabriela Sálvio M.D., Vanderlei S. Bagnato, Brian C. Wilson, Cristina Kurachi

Author Affiliations +

Proceedings Volume 10467, Photonics in Dermatology and Plastic Surgery 2018; 104670U (2018) https://doi.org/10.1117/12.2288539
Event: SPIE BiOS, 2018, San Francisco, California, United States

Abstract

Melanoma is the most aggressive type of skin cancer with high rates of recurrence, morbidly and mortality. Current standard treatment involves surgery, chemotherapy, immunotherapy and also radiation therapy but the response is limited to early-stage tumors. Photodynamic therapy (PDT) is already established as an effective therapeutic option for cutaneous pre-malignant lesions and non-melanoma skin cancer but has shown very limited efficacy for pigmented lesions as melanoma, where the high melanin absorption limits light penetration, preventing complete treatment. Optical clearing agents (OCA) are hyperosmotic agents that work by dehydrating tissue and matching the tissue refractive index, thereby reducing scattering and improving light penetration. here, OCA was used in combination with single and dual photosensitizer-based PDT, targeting the tumor cells and vasculature to improve treatment response in both melanotic and amelanotic melanoma models in vivo. Vascular-targeted PDT was more efficient for amelanotic tumors, independent of the use of OCA and could treat the whole tumor in a single treatment session. However, for the melanotic tumors, OCA significantly improved PDT response for the both vascular-targeted and dual-agent PDT. The best result was obtained with the latter, resulting in no tumor being detected by H&E staining and S100 immunostaining. These initial pre-clinical results show the potential use of dual agent PDT enhanced by OCA for the treatment of pigmented cutaneous melanoma.

Conference Presentation

Citation Download Citation

Layla Pires, Ana Gabriela Sálvio M.D., Vanderlei S. Bagnato, Brian C. Wilson, and Cristina Kurachi "Preclinical studies of dual-photosensitizer PDT combined with optical clearing for treatment of cutaneous melanoma (Conference Presentation)", Proc. SPIE 10467, Photonics in Dermatology and Plastic Surgery 2018, 104670U (14 March 2018); https://doi.org/10.1117/12.2288539

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
PRESENTATION

WATCH
PRESENTATION SAVE TO MY LIBRARY

GET CITATION

KEYWORDS

Photodynamic therapy

Melanoma

Tumors

Optical clearing

Light scattering

Skin cancer

Tissue optics

Show All Keywords

Keywords/Phrases

Search In:

Publication Years